Lilly CEO Lechleiter detailed registry plans at Indianapolis speech
INDIANAPOLIS, Sept. 24 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company (NYSE: LLY) announced that it is set to become the first pharmaceutical research company to disclose its payments to physicians in the United States.
At a speech before the Economic Club of Indiana today, Lilly's president and chief executive officer, John Lechleiter, Ph.D., outlined the company's plans to launch an online registry of physician payments in 2009. Lechleiter announced the physician registry as a part of a broader outline on the company's transformation efforts.
"With each of our industry firsts, from launching our clinical trials registry to the public reporting of educational grants, Lilly is striving to be a leader in improving transparency across our industry," said Lechleiter. "As Lilly continues to look for more ways to be open and transparent about our business, we've learned that letting people see for themselves what we're doing is the best way to build trust."
Earlier this year, Lilly was the first pharmaceutical research company to endorse bipartisan federal legislation - known as the Physician Payments Sunshine Act - that would establish a national registry of payments to physicians by medical device, medical supply and pharmaceutical companies. The legislation, which was introduced by United States Senators Charles Grassley (R-Iowa) and Herbert Kohl (D-Wisconsin) last September, has not been passed yet by Congress.
Lechleiter added, "Though we remain hopeful that the Sunshine Act will
be passed by Congress at some point, Lilly is taking action independently.
Being more transparent by opening up our business to the public is an
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved